| Document |
Document Title |
|
WO/2021/158646A1 |
Provided herein are methods and compositions for treating von Willebrand disease with platelets, platelet derivatives, and/or thrombosomes.
|
|
WO/2021/157625A1 |
Provided is a novel neovascularization device. The neovascularization device contains a neovascularization component and a polymer. The polymer optionally contains, for instance, at least one or more polyvinyl alcohol resins (A) select...
|
|
WO/2021/158622A1 |
Provided herein are methods for preparing anti-fibrinolytic loaded platelets, platelet derivatives, thrombosomes and compositions thereof.
|
|
WO/2021/157626A1 |
Provided is a novel angiogenesis device. This angiogenesis device, which comprises an angiogenesis component and a polymer, is for inducing angiogenesis in a transplantation site of a cell- or tissue-containing device. The polymer may ...
|
|
WO/2021/158583A1 |
The present disclosure relates to agents, compositions targeting to von Willebrand factor (VWF). The VWF targeting agents are synthetic polynucleotides, including VWF binding agents and their reversal agents. The VWF binding agents are V...
|
|
WO/2021/158799A1 |
Curative and prophylactic therapies for microvascular and/or macrovascular thrombosis are provided, as are prophylactic therapies capable of preventing fibrinolysis shutdown and therapies for non-thrombotic disorders. Methods provide for...
|
|
WO/2021/158625A1 |
Provided herein are methods and compositions for treating acquired hemophilia with platelets and/or platelet derivatives. In some cases, the platelets and or platelet derivatives are loaded with an anti-fibrinolytic.
|
|
WO/2021/157732A1 |
A composition for lysing at least one type of staphylococcus bacteria selected from the group consisting of Staphylococcus hyicus, Staphylococcus chromogenes, Staphylococcus simulans, Staphylococcus schleiferi, and Staphylococcus felis, ...
|
|
WO/2021/153719A1 |
[Problem] To provide a medicinal composition having a novel use that comprises a dental pulp-derived pluripotent stem cell preparation available for humans. [Solution] A medicinal composition that comprises dental pulp-derived stem cells...
|
|
WO/2021/154922A1 |
The levels of prouroguanylin (proUGN), or fragments thereof, present in blood are normally low in humans and are proposed to be involved in the physiologic regulation of oral and vascular salt levels in the body. When certain kidney rela...
|
|
WO/2021/153716A1 |
It is an object of the present invention to provide a controlled release composition which can prevent a sudden rise in the blood concentration of an active ingredient and can maintain the blood concentration for a long time.
|
|
WO/2021/154987A1 |
Solid state forms of Mitapivat, Mitapivat hemisulfate, Mitapivat HCl, Mitapivat phosphate, Mitapivat hemisulfate:ascorbic acid and Mitapivat hemisulfate:adipic acid, processes for preparation thereof, pharmaceutical compositions thereof,...
|
|
WO/2021/155004A1 |
Disclosed herein, inter alia, are compounds for binding STRAD pseudokinase and uses thereof.
|
|
WO/2021/153665A1 |
The present invention provides a compound that has an inhibitory effect on DYRK and that is represented by general formula (I) (in the formula, Q, R1, R2, and R3 are as defined in the description).
|
|
WO/2021/154122A2 |
The invention relates to organic chemistry, and more particularly to novel modifications of the compound 5-chloro-N-({(5S)-2-oxo-3-[4-3-oxo-4-morpholinyl-phenyl]-1,3
-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide, named L- and U-modifi...
|
|
WO/2021/152066A1 |
The present invention relates to bispecific antibodies capable of binding to coagulation Factor IX (FIX) and/or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and/or the activated form thereof Factor Xa (FXa) and promoti...
|
|
WO/2021/152192A1 |
The present invention relates to low and very low molecular weight heparin compositions for use in the treatment of deep vein thrombosis, wherein the low or very low molecular weight heparin composition is administered at a dose of 110-1...
|
|
WO/2021/153199A1 |
This iron-containing composition contains iron (iii) pyrophosphate, a polyvalent alcohol, gum arabic, and gum ghatti. The polyvalent alcohol content is 93-630 parts by mass relative to 100 parts by mass of iron (iii) pyrophosphate. The t...
|
|
WO/2021/148720A1 |
A vascular adhesion protein-1 (VAP-1) inhibitor can be used as a regulator of reactive oxygen species (ROS) concentration in ex vivo culturing of hematopoietic stem cells, which enables a method of producing an expanded population of hem...
|
|
WO/2021/150187A1 |
The present invention relates to a capsule-in-capsule composition comprising dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof characte...
|
|
WO/2021/150488A1 |
The present invention is directed to improved methods of preparing cells and compositions for therapeutic uses. In particular, the invention is concerned with methods which inhibit platelet activation and/or cell differentiation during t...
|
|
WO/2021/148983A1 |
The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to E-selectin. The invention includes uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.
|
|
WO/2021/072780A9 |
The present application provides methods and compositions for treating diseases or disorders related to hematopoietic dysfunctions and/or injuries, or for rejuvenating HSPCs.
|
|
WO/2021/147923A1 |
Provided are a vesicle and the use thereof. The vesicle is an induced vesicle, and the sources thereof include stem cells or somatic cells, and the possessed markers include Syntaxin 4. Compared with an exosome in mesenchymal stem cells,...
|
|
WO/2021/150795A1 |
The present disclosure relates to methods of making of one or more bioengineered ferritin proteins having a preselected ratio of H-subunits (ferritin heavy chain (FTH or H)) to L-subunits (ferritin light chain (FTL or L)). The disclosure...
|
|
WO/2021/147635A1 |
The present invention relates to the field of medical preparations, and specifically relates to a filling composition and a filling preparation for endoscopic minimally invasive surgery. The acetylcysteine-containing filling preparation ...
|
|
WO/2021/145755A1 |
The invention relates to medicine and can be used for reducing the adverse effects of air travel on human health. A method includes the taking of preparations which increase blood osmolarity. An aqueous solution for peroral rehydration i...
|
|
WO/2021/146291A1 |
Compositions containing self-assembling peptides and/or self-assembling peptidomimetics ("self-assembling peptides") can be used to create a long-lasting "lift" or means of elevating tissue to be resected, dissected, manipulated or repai...
|
|
WO/2021/146160A1 |
Provided herein are methods of treating and preventing hereditary angioedema attack in pediatric subpopulations using antibodies binding to active plasma kallikrein with specific treatment regimens, for example, at about 150 mg every two...
|
|
WO/2021/126977A9 |
Provided herein are methods of treating IgA nephropathy, comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, to a subject in need thereof. Also provided herein are met...
|
|
WO/2021/141507A1 |
The invention relates to a new group of aromatic sulphonamides derivatives of formula (I) and their synthesis and use for modulation of the activity of protein disulfide isomerase (PDI). More particularly, the invention provides small mo...
|
|
WO/2021/139740A1 |
The present invention relates to a tetrahydrocannabinol derivative and the medical use thereof. Specifically, the present invention relates to a pyrimidine derivative as shown in general formula (I) or a stereoisomer, a solvate, a metabo...
|
|
WO/2021/140488A1 |
A method for preparing a bovine myoglobin includes: constructing a first plasmid containing genes for heme biosynthesis pathway enzymes; constructing a second plasmid containing a gene for Bos taurus myoglobin MYG; constructing a first E...
|
|
WO/2021/139756A1 |
The present disclosure relates to a tricyclic tetrahydroisoquinoline derivative, a preparation method therefor and an application thereof in medicine. In particular, the present disclosure relates to a tricyclic tetrahydroisoquinoline de...
|
|
WO/2021/140489A1 |
A method for preparing a porcine myoglobin includes: constructing a first plasmid containing genes for heme biosynthesis pathway enzymes; constructing a second plasmid containing a gene for Sus scrofa myoglobin MYG; constructing a first ...
|
|
WO/2021/141506A1 |
The invention relates to a new group of aromatic sulphonamides derivatives of formula (I) and their synthesis and use for modulation of the activity of protein disulfide isomerase (PDI). More particularly, the invention provides small mo...
|
|
WO/2021/142171A1 |
Methods and compositions for treatment of paroxysmal nocturnal hemoglobinuria are described. In some aspects, the disclosure features a method of treating a subject suffering from paroxysmal nocturnal hemoglobinuria (PNH), comprising sub...
|
|
WO/2021/141066A1 |
The present invention pertains to a platelet aggregator that contains amorphous polyphosphoric acid as an active ingredient, wherein the polyphosphoric acid is a Ca salt of polyphosphoric acid. The platelet aggregator acts on damaged gas...
|
|
WO/2021/136390A1 |
A blood coagulation factor XIa inhibitor of formula I, a pharmaceutical composition containing same, a preparation method therefor, and use thereof in preparation of drugs for prevention or treatment of thrombosis and embolism-related di...
|
|
WO/2021/135071A1 |
Disclosed is a use of piperazine ferulate tablets in the preparation of medicaments for preventing and treating anemia. The piperazine ferulate tablets can obviously improve the content of erythropoietin and further promote bone marrow t...
|
|
WO/2021/132661A1 |
The present invention relates to a method of constructing a library that includes two or more types of cyclic peptides, involving: a step for preparing an mRNA library that codes peptides which include a sequence represented in formula (...
|
|
WO/2021/132627A1 |
The present invention addresses the problem of providing a culturing method and a production method for hematopoietic stem cells which can be used for hematopoietic stem cell transplantation. The method for culturing hematopoietic stem c...
|
|
WO/2021/133660A1 |
Provided are methods for clinical treatment of pregnancy-associated atypical haemolytic uraemic syndrome (p-aHUS), including postpartum aHUS, using an anti-C5 antibody, or antigen binding fragment thereof, such as ravulizumab (ULTOMIRIS®).
|
|
WO/2021/133874A1 |
Methods and compositions for producing fetal hemoglobin and treating a hemoglobinopathy or thalassemia are disclosed.
|
|
WO/2021/123799A1 |
The invention relates to red blood cell-derived vesicles comprising encapsulated active agents, their use in therapy and methods of production thereof.
|
|
WO/2021/127525A1 |
This disclosure relates to pharmaceutical formulations of anti-Factor XI and/or activated Factor XI (Factor XIa) antibodies, or antigen-binding fragments thereof. Also provided are dosage regimens for such antibodies or antigen-binding f...
|
|
WO/2021/124172A1 |
The present disclosure relates to compounds of formula (I') and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in th...
|
|
WO/2021/121396A1 |
Provided is a tricyclic plasma kallikrein inhibitor compound having a novel structure, good activity and high selectivity, which can be widely used in the prevention or treatment of diseases related to a plasma kallikrein activity.
|
|
WO/2021/124272A1 |
The present application discloses a compound of formula (I) or a salt thereof: (I) and compositions comprising such compound or salt thereof. The use of such compound, salt thereof or composition comprising same for treating anemia or le...
|
|
WO/2021/123090A1 |
Expression of lambda antibody light chain with non-native leader sequence, wherein light chain is sequence-engineered to restore native N terminus. Immunoglobulin lambda variable domain sequence comprising N terminal deletion for express...
|
